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A B S T R A C T
Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder
associated with aberrant production of beta-amyloid (Aβ) peptide depositing in brain as amyloid plaques. While
animal models allow investigation of disease progression and therapeutic efficacy, technology to fully dissect the
pathological mechanisms of this complex disease at cellular and vascular levels is lacking.
X-ray phase contrast tomography (XPCT) is an advanced non-destructive 3D multi-scale direct imaging from the
cell through to the whole brain, with exceptional spatial and contrast resolution. We exploit XPCT to simulta-
neously analyse disease-relevant vascular and neuronal networks in AD mouse brain, without sectioning and
staining. The findings clearly show the different typologies and internal structures of Aβ plaques, together with
their interaction with patho/physiological cellular and neuro-vascular microenvironment. XPCT enables for the
first time a detailed visualization of amyloid-angiopathy at capillary level, which is impossible to achieve with
other approaches.
XPCT emerges as added-value technology to explore AD mouse brain as a whole, preserving tissue chemistry
and structure, enabling the comparison of physiological vs. pathological states at the level of crucial disease
targets. In-vivo translation will permit to monitor emerging therapeutic approaches and possibly shed new light
on pathological mechanisms of neurodegenerative diseases.
1. Introduction
The use of animal models to mimic neurodegenerative disorders al-
lows the investigation of neuropathogenic mechanisms and the moni-
toring of disease progression and therapeutic efficacy (Balducci and
Forloni, 2011). This is particularly important for research on Alzheimer's
disease (AD), based on the complexity of its neuropathology involving
synaptic and cognitive dysfunction, neuroinflammation, brain
angiopathy, neuronal cell death, and gross brain atrophy (Selkoe, 2011).
The causes and progression of AD are not well understood as yet. The
main histopathological brain lesions of AD patients are represented by
extracellular senile plaques composed of Aβ aggregates, and by intra-
cellular neurofibrillary tangles enriched in hyperphosphorylated tau
protein.
One of the unmet needs common to neurodegenerative diseases of the
CNS, including AD, is the possibility to investigate crucial
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2neuropathological signatures and therapeutic efficacy at the fine level.
Ideally, this would require direct imaging of the whole brain in a 3D
fashion, rather than of isolated slices of brain tissue having undergone
blood removal, freezing at extremely low temperature, and manipulation
with aggressive fixatives and various detergents. Direct 3D-imaging
would allow simultaneous analyses of (i) brain alterations in various
cell populations (neuronal loss, gliosis, peripheral infiltrates); (ii) struc-
tural changes in terms of cell density and organization (brain atrophy);
(iii) modifications in vascular networks and integrity (cerebral amyloid
angiopathy).
The ambitious possibility to achieve a 3D-imaging of the highly
complex neuronal and vascular networks communicating with disease-
relevant cells, while preserving tissue chemistry, is not possible with
conventional indirect immunohistochemical techniques, as these neces-
sitate chemical tissue manipulation to add fluorescence/chromogenic
reporters. Magnetic resonance imaging help circumvent these problems,
but remains limited by spatial resolution of a fewmm (Dona et al., 2016).
In contrast, X-ray tomography overcomes spatial resolution limits;
however, it fails to image soft tissues. Such a lack can be filled by X-ray
phase contrast tomography (XPCT), which makes possible multi-scale 3D
biomedical imaging of neuronal and vascular networks ranging from
cells through to brain as a whole (Bukreeva et al., 2017; Cedola et al.,
2017; Fratini et al., 2015). XPCT is particularly useful for low-absorbing
bio-medical samples, with a gain in contrast resolution reaching up to
1000 folds that of conventional tomography. XPCT, with its high reso-
lution and large field of view, is rapidly gaining importance in the
investigation of neurodegenerative diseases, such as AD and multiple
sclerosis (Pinzer et al., 2012).
2. Materials and methods
2.1. Animals
APPswe/PS1dE9 (APP/PS1) transgenic male mice [B6C3-Tg(APPswe,
PSEN1dE9)85Dbo/Mmjax mice] and age-matched WT littermates were
purchased from Jackson Laboratories (USA). All procedures involving
animals and their care were conducted according to European Union
(EEC Council Directive 86/609, OJ L 358,1; 12 December 1987) and
Italian (D.L. n.116, G.U. suppl. 40, 18 February 1992) laws and policies.
They were reviewed and approved by the Mario Negri Institute Animal
Care and Use Committee.
2.2. Preparation of the samples for XPCT and nano-XPCT
The preparation of the samples for ex-vivo XPCT is necessary to
ensure the integrity of the tissue that would otherwise degrade. However,
as widely shown, it preserves the structure and chemistry of the tissues.
Nano-XPCT requires a sample preparation similar to that used for SEM
experiments, but tissue chemistry is still preserved.
XPCT: Mice were killed under CO2 to drastically reduce bleeding.
Brains were removed, placed in paraformaldehyde for 24 h, and stored in
70% EtOH at 4 C until analysis. Prior to XPCT analysis, the samples were
included in agar agar, which keeps them hydrated and prevent both ra-
diation damage and movement of the samples during the measurement.
Nano-XPCT: Hippocampus were dissected out and placed in 2.5%
gluteraldehyde in 0.1M cacodylate buffer, pH 7.2, for 3 h at room tem-
perature. Samples were post-fixed in osmium tetroxide (1% in 0.1M
cacodylate buffer, pH 7.2; 1 h) and uranyl acetate (1% in water; 1 h),
dehydrated through a graded ethanol series (70/95/100%), put in pro-
pylene oxide, and embedded in epoxy resin (Sigma-Aldrich, St. Louis, MO
63103 USA) at 42 C overnight and for 2 days at 60 C.
2.3. Experimental XPCT and nano-XPCT set-ups
i) The XPCT experiment used monochromatic incident X-ray energy at
17 keV. The sample-detector distance was set at 5 cm. The detector
has an effective pixel size of 1.625 μm. The tomography was produced
by means of 3000 projections covering a total angle range of 360.
The acquisition time for each angular position was 50ms. The total
brain volume was acquired in about 15min. We exploited the half-
acquisition mode, which pertains specifically the acquisition of
sample horizontally larger than the field of view (FOV) of the camera.
In this acquisition mode the sample is positioned outside the rotation
center of the stage so that half of the sample is outside the FOV. We
acquired over an angular range of 360. The projections acquired
during the first 180 will provide information on the first part of the
sample, while the projections acquired from 180 to 360 will provide
information on the sample region which was initially out of the FOV.
Data pre-processing, phase retrieval and reconstruction were per-
formed with SYRMEP Tomo Project software (Brun et al., 2017; Massimi
et al., 2018) and optimized scripts. Image analysis was performed using
ImageJ and the 3D rendering images were obtained using VG studio Max
software.
ii) The nano-XPCT experiments were carried out at Nano-Imaging ID16A
beamline of the ESRF. A pair of multilayer coated Kirkpatrick-Baez
optics was used to focus the X-rays (~30 nm) at 17 keV. The sample
is put in the divergent beam downstream of the focus to produce
magnified phase contrast images. The projection geometry also al-
lows zooming into specific regions of a large sample by combining
scans with different magnifications and fields of view (Bartels et al.,
2015; Mokso and Cloetens, 2007). By measuring the Fresnel diffrac-
tion patterns at different effective propagation distances, the phase
maps of the sample can be retrieved via holographic reconstruction,
this so-called phase retrieval procedure (Cloetens et al., 1999) being
implemented using GNU Octave software. Magnified radiographs
were recorded onto an X-ray detector using a FReLoN
charged-coupled device. For one tomography scan, 1500 projections
were acquired with 0.32 s exposure time and 50 nm effective pixel
size. Tomography scans at four different foci to sample distances were
acquired to complete one holotomography scan. The tomographic
reconstruction was obtained with ESRF PyHST software package.
2.4. Transmission electron microscopy
Samples were prepared as for nano-XPCT and ultrathin sections
(50 nm) were cut with a Leica EM UC6 ultramicrotome (Leica Micro-
systems, Vienna, Austria), counterstained with lead citrate (0.004% in
water) and examined with an energy filter transmission electron micro-
scope (EFTEM Libra120, Carl Zeiss NTS GmbH, Oberkochen, Germany).
2.5. Immunofluorescence for astrocytes, axons, and amyloid plaques
APP/PS1 coronal brain cryostat sections were collected in 100mM
PBS for immunofluorescence analysis of astrocytes, and axons, and
double-stained for amyloid plaques. Freely-floating brain slices were
incubated overnight at 4 C with the primary antibodies against MAP2
(1:2000, Abcam; 24 h, 4 C) for axons; GFAP (1:3500; Chemicon Int. Inc.,
Temecula, USA) for astrocytes, followed by incubation with the appro-
priate secondary antibodies conjugated with either Alexa 546 or Alexa
695 (1:500, Molecular Probes). Plaques were revealed by exposure of the
slices to the fluorescent dye X34.
2.6. Structured illumination microscopy (SIM)
SIM analysis of brain sections was performed on a Nikon SIM system.
Tissues were imaged at laser excitation of 405 (for X34), 561 (for MAP-2)
and 640 (for GFAP) nm with a 3D-SIM acquisition protocol. Sixteen-bit
images sized 1024 1024 pixels with a single pixel of 0.030 μm were
acquired in a grey-level range of 0–16000 to exploit the linear range of
the camera (iXon ultra DU-897U, Andor) and to avoid saturation. Three-
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3dimensional Z-stacks were scanned with a 0.125 μm step size over
2–3 μm. Raw and reconstructed images were validated with the SIM-
check plugin of ImageJ (Ball et al., 2015) to rule out image artifacts
(Demmerle et al., 2017; Culley et al., 2018).
Only those meeting validation criteria as shown in Fig. S1 were
included in the study. Images were finally managed with GIMP (Gnu
Image Manipulation Program).
3. Results
Here, we present an extensive multi-scale investigation of the AD
mouse brain imaged with XPCT, providing the 3D structure of the hip-
pocampus at micro and nano scale and the description of the internal
structure of amyloid plaques, capillaries, and of their interaction with the
surrounding brain microenvironment, including neurons and glial cells.
We used the APP/PS1 mouse AD model. These mice carry a Swedish
human mutation in the amyloid precursor protein (APP) gene and a
deletion of exon 9 on the presenilin 1 (PS1) gene (Jankowsky et al.,
2001). APP/PS1 mice are the AD model most widely used and best
characterized by us and others (Balducci et al., 2014; Gregori et al., 2017;
Mancini et al., 2017), with Aβ plaques starting to be detectable around
the age of 6–8 months (Holcomb et al., 1998), accompanied by intense
inflammation, atrophy, and vascular damage in brain.
Two XPCT experiments in free-space propagation mode (Bravin et al.,
2013) were performed with respective spatial resolutions of 1.625 μm
(voxel side) at Tomcat-SLS in Villigen, Switzerland, and 50 nm (equal in
the three directions) at ID16A-ESRF in Grenoble, France, used previously
for nano-3D neuro-imaging of spinal cord of mice affected with experi-
mental multiple sclerosis (Cedola et al., 2017), and of brain tissue of
naïve mice (Khimchenko et al., 2016). In the first experiment, we ob-
tained 3D imaging of the whole brain down to plaques and cells. In the
second experiment, we explored the internal structure of the amyloid
plaques and capillaries, and described their interaction with the sur-
rounding brain microenvironment. We present the data obtained on a
wild-type (WT) mouse and an APP/PS1 mouse.
Fig. 1 demonstrates that XPCT has the potentiality to dissect AD brain
from the whole organ to the fine neuropathology. Thus, a virtually
selected 450-μm-thick portion of whole brain is shown in Fig. 1a, while
Fig. 1b–c shows a portion of the hippocampal region.
We easily distinguish both absence (Fig. 1b) and presence (Fig. 1c)
of Aβ plaques in WT and APP/PS1 mouse hippocampus, respectively.
The insets of Fig. 1c show single Aβ plaques in details, which are clearly
different in structure. We could classify plaques as two different kinds,
neuritic plaques with a dense core and neuritic plaques without a core.
In the classification of plaques, the term “neuritic plaques” originates
from the typical presence of dystrophic neuronal processes (dystrophic
neurites) in the plaque corona surrounding the central dense nucleation
core, and differences in plaque features are normally attributable to a
different stage of plaque development (Duyckaerts et al., 2009; Perl,
2010).
Through nano-XPCT, with a spatial resolution of 50 nm, we imaged
inside the plaques. It should be noted that in the nano-tomography im-
ages presented, the grey levels are inversely proportional to the density,
with black corresponding to high-density structures, whereas white
corresponds to low-density structures.
As observed in Fig. 1d, we could detect a typical neuritic plaque with
a central nucleation core (Han et al., 1995); as demonstrated through
transmission electron microscopy (EM), these cores are enriched in Aβ
fibrils (Fig. 1e). We could also detect a different type of neuritic plaque
without a central core (Fig. 1f). Both plaques were surrounded by
dystrophic neurites (red arrows), widely described in both AD mouse
(Blanchard et al., 2003) and patient brains (Su et al., 1993). Again, EM
confirmed this pathological detail evidenced by nano-XPCT (Fig. 1g).
Fig. 1 panels h and i show a 3D rendering of several deposited Aβ
plaques and of a single Aβ plaque, respectively, as obtained from
nano-XPCT.
XPCT is also unique in permitting a very detailed analysis of the
whole brain vasculature. In particular, Fig. 2a–d shows different
Fig. 1. XPCT allows a deep investigation of Aβ plaques. a) 3D XPCT-rendering of the virtually selected portion of mouse brain. Micro-XPCT images showing b)
absence of plaques and c) clearly detectable Aβ plaques in hippocampus of WT and APP/PS1 mice, respectively. (Scale bar¼ 200 μm). Magnified insets in (c) show
both neuritic cored and non-cored plaques indicated with blue and yellow arrows respectively in the smaller magnification image. (Scale bar¼ 30 μm). d) Nano-XPCT
image (scale bar¼ 5 μm) of a cored neuritic plaque, with EM photograph (e) showing Aβ fibrils inside plaque cores (scale bar¼ 500 nm). f) Nano-XPCT image (scale
bar¼ 5 μm) of a non-cored neuritic plaque enriched in dystrophic neurites inthe plaque corona. Red arrows in both d and f indicate dystrophic neurites. g) EM
photograph confirming the presence of dystrophic neurites around plaques (scale bar¼ 500 nm). h) 3D rendering of deposited Aβ plaques and i) of a single Aβ plaque.
Grey levels are proportional to tissue density as follows: in XPCT images (b, c), high-density structures appear white, whereas low-density structures appear black; in
nano-XPCT (d, f), the grey levels are inverted.
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4enlargements of 3D renderings of the blood vessel network of the whole
hippocampus, in 23-month-old WT and APP/PS1 mice, respectively,
providing information on the status of the brain vasculature in terms of
vessel integrity and distribution. It is worthwhile to remark that only a
3D imaging of thick sample volume allows to follow the trajectory of the
vessels and thereby permitting this kind of investigation. The comparison
of WT (Fig. 2a and b) and APP/PS1 (Fig. 2c and d) mice provides in-
formation on the presence of eventual vascular alterations related to AD.
Fig. 2. XPCT shows vascular alterations in AD mouse brain. a-d) Micro–XPCT 3D-renderings of (a-b) normal blood vasculature in WT mouse brain, and (c-d)
evidence of vessel loss (d, white frame) and interruptions (d, white arrows) in APP/PS1 mouse brain. e-f) Nano-XPCT images of brain capillaries of APP/PS1
mouse brain showing the presence of Aβ deposits inside the lumen (scale bar¼ 5 μm), which completely occlude the vessels (red arrows in (e)), or on vessel walls
leading to a clear reduction in lumen volume (red arrows in (f)). The yellow arrow in (f) indicates an endothelial cell at the wall of the capillary. Plaques are also
well distinguishable in close proximity to vessels. g) Nano-XPCT image showing an apparent interaction between a deposited plaque and a capillary through
astrocyte end-feet (blue arrow).
Fig. 3. Nano-XPCT describes AD mouse brain microenvironment. a) Nano-XPCT image (scale bar¼ 5 μm) showing hippocampal microenvironment enriched in
deposited Aβ plaques and widely populated by astrocytes. b) Zoom of a single astrocyte whose processes surround the plaque (scale bar¼ 5 μm). c) Super-resolution
immunofluorescence images (scale bar¼ 2 μm) of APP/PS1 brain slices stained for plaques and astrocytes, to show an astrocyte surrounding the plaque. d-e) Nano-
XPCT images where neuronal axons are well visible across and near plaques (red arrows) (scale bar¼ 5 μm). f) Immunofluorescence images of a mouse brain slice
stained for plaques and axons. g) Nano-XPCT image shows the clear presence of both healthy (yellow arrows) and suffering (red arrows) neurons. h) 3D-rendering of
the microenvironment in APP/PS1 mouse brain. Violet: astrocytes; red: capillaries; brown: plaques; green: dystrophic neurites.
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5In the WT mouse, micro-vessels appear normally branched and distrib-
uted throughout the brain parenchyma, displaying no signs of vessel wall
breakages, as can be seen in a detail shown in Fig. 2b (white frame). In
contrast, Fig. 2c and d provides details on vessel status in the brain of a
23-month-old APP/PS1 mouse, with an apparent reduction in blood
vessels detected in the same area (white frame). As indicated by the
white arrows, some of the remaining vessels appear damaged with
evident wall interruptions, as already described through XPCT in
experimental multiple sclerosis (Cedola et al., 2017).
Through nano-XPCT, we collected further neuropathological details
at the capillary level (Fig. 2 e-g). This enabled the exploration of the
intra-capillary lumen (Fig. 2e), including the visualization of endothelial
cells at the walls of the capillary (yellow arrow in Fig. 2f), and revealed
the presence of Aβ deposits inside the capillary lumen (red arrows in
Fig. 2e) and at the vessel walls (red arrows in Fig. 2f). Abnormality of
vessel walls is considered as the main cause of brain hypo-perfusion in
AD (Allen et al., 2014); XPCT provides additional information on angi-
opathy, particularly at capillary level, which cannot be obtained with
standard techniques.
Nano-XPCT also enabled imaging of the typical ‘glial barrier’, which
consists of astroglial end-feet surrounding the BBB and covering the
majority of the parenchymal vasculature (Yamazaki and Kanekiyo,
2017). Of note is the recent demonstration of the so-called glymphatic
system, a macroscopic waste clearance system of the neurovascular unit
which utilizes a unique system of perivascular tunnels, made of astroglial
cells which regulate a continuous interchange between CSF and inter-
stitial fluid. This system apparently promotes efficient elimination of
soluble proteins andmetabolites from the CNS including Aβ (Jessen et al.,
2015). Interestingly in this context, Fig. 2g shows an astrocyte (blue
arrow in Fig. 2g) interconnecting a neuritic plaque with an apparently
damaged capillary.
Nano-XPCT also permitted a detailed imaging of the microenvi-
ronment encountered around neuritic plaques and typifying an AD
brain and its cellular complexity (Fig. 3). Thanks to the depth infor-
mation, provided by 3D imaging and which cannot be obtained via 2D
imaging, the distribution in space of the tissue components can be
visualized.
In particular, Fig. 3a shows three neuritic plaques (red arrows) sur-
rounded by astrocytes. Fig. 3b shows a zoom of astrocyte-plaque contact
in a different zone of the same sample. Astrocytes in the periphery of the
corona of plaques are widely described in the literature (Duyckaerts
et al., 2009), and our nano-XPCT observation is supported by our
immunofluorescence analysis of Aβ plaques (Fig. 3c) and astrocytes. In
3D reconstruction, images acquired in super resolution optical micro-
scopy clearly show an astrocyte surrounding the plaque (Fig. 3c), con-
firming the reliability of nano-XPCT.
Thin filaments (1–3 μm in diameter), compatible with myelinated
axons, were also detectable (Fig. 3d), some of which pass across the
plaques, as can be seen in Fig. 3e (red arrows). Super-resolution immu-
nofluorescence imaging, which demonstrated that these filaments were
positive for MAP-2 (Fig. 3f), a marker for axons, support the description
of the microstructures observed through XPCT.
In addition to its ability to image simultaneously Aβ plaques, astro-
cytes, and vessels, nano-XPCT permitted to investigate neuronal cells at
distance or in close proximity to plaques.
Notably, we could detect the coexistence of both healthy and
suffering neurons in the same zone. Thus, Fig. 3g shows normally
shaped neurons (yellow arrows) with a typical dense cytoplasm
(rendered as grey), indicative of pathology-spared neurons, and neu-
rons smaller in size, with a whiter cytoplasm and a very small nucleus
(red arrows) such as typically encountered in neuronal degeneration
(Kuljis et al., 1997).
Fig. 3h is a 3D rendering that summarizes the potential of nano-XPCT
in describing a typical microenvironment encountered in an AD mouse
brain populated by plaques, where astrocytes are marked in violet, cap-
illaries in red, and plaques in brown.
4. Conclusions
We herein demonstrate that XPCT holds the great advantage of
allowing a 3D detailed investigation of the brain microenvironment in its
real complexity. It permitted the reliable description of the neuropath-
ological context encountered in different brain areas of an AD mouse
model mimicking the human pathology where neuronal and vascular
networks are compromised. XPCT allowed us not only to evidence the
main pathological lesions of AD, such as deposited extracellular senile
plaques and the presence of dystrophic neurites populating plaque
corona, but also to distinguish different typologies of plaques. We could
detect the presence of astrocytic processes around plaques, such as occurs
in the brain of AD patients (Duyckaerts et al., 2009), and connections
between plaques and capillaries through astrocytic end-feet. At vascular
level, we observed capillaries featuring deposits which reduced the vessel
lumen, and are likely attributable to the presence of deposited Aβ. As
widely described also in the literature, we observed the presence of
suffering neurons close to plaques, and healthy neurons at a certain
distance from them (Mucke and Selkoe, 2012).
The possibility to faithfully image brain conditions in a 3-dimension
and in such an exhaustive manner, without tissue manipulation, is a
unique opportunity to dissect the neuropathology down to nano-sized
details, thereby gaining a more comprehensive understanding of it.
Most importantly, through XPCT we will be able to evaluate the efficacy
of new therapeutic approaches in experimental models at the level of the
multiple crucial neuropathological targets of AD and other neurodegen-
erative diseases.
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